In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate ACE-031 (ramatercept) | Natural fragment Teriparatide (PTH 1-34) | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Natural fragment | |
| Area | Recovery and repair | Recovery and repair | |
| Evidence | |||
| Amount of evidence | 34 | 2,709 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 5 (5 in people) | 209 (168 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 4 | 168 · 15 active30 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | ACE-031 (ramatercept) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointWhole body | 22 | 2,228128691326 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients”
| Adverse eventsWhole body | 55 | 16313726 |
|---|
| PharmacokineticsPharmacology | 33 | 30273 |
|---|
| Exercise and physical functionMusculoskeletal | 11 | 1818 |
|---|
| Muscle injury and repairMusculoskeletal | 21318 | 11 |
|---|
| Body weightMetabolic and weight | 211 | 1028 |
|---|
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 4 trials, ranked by phase, then posted results and enrollment: 1 completed · 2 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA24 participantsApr 2010 to Jun 2011
Duchenne Muscular Dystrophy
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA11 participantsOct 2010 to May 2011
Duchenne Muscular Dystrophy
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA70 participantsAug 2009 to Feb 2011
Muscular Atrophy
Top 3 of 168 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Radius Health, Inc.2,463 participantsApr 2011 to Oct 2014
Osteoporosis · Postmenopausal Osteoporosis
Eli Lilly and Company1,366 participantsOct 2012 to Jul 2016
Postmenopausal Osteoporosis
Eli Lilly and Company712 participantsJun 2006 to Jun 2010
Osteoporosis, Postmenopausal · Back Pain · Spinal Fracture
30 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | ACE-031 (ramatercept) | Teriparatide (PTH 1-34) |
|---|---|---|
| Bone and jointMusculoskeletalCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 7.2% Lumbar spine BMD change Dose studied: 20 microg once daily18 monthsn = 4282007 |
| Exercise and physical functionMusculoskeletalCompared as: value in the arm that got the peptide, in s | No comparable result 1 randomized-trial result measure it in another way or another unit. | −3.2 to −5.9 s TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks Dose studied: 20 μg every day78 weeksn = 1712017 |
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 5 randomized-trial results measure it in another way or another unit. | 10% Nasopharyngitis Dose studied: 20 μg once daily12 monthsn = 4322017 |
No comparable result
2 randomized-trial results measure it in another way or another unit.
7.2%
Lumbar spine BMD change
Dose studied: 20 microg once daily18 monthsn = 4282007
No comparable result
1 randomized-trial result measure it in another way or another unit.
−3.2 to −5.9 s
TUG time difference versus risedronate · teriparatide minus risedronate, 6 to 26 weeks
Dose studied: 20 μg every day78 weeksn = 1712017
No comparable result
5 randomized-trial results measure it in another way or another unit.
10%
Nasopharyngitis
Dose studied: 20 μg once daily12 monthsn = 4322017